Envafolimab, a subcutaneous PD-L1 antibody developed by Simcere Zaiming in collaboration with Alphamab Oncology (9966.HK) and 3D Medicines (1244.HK) i...
December 23, 2025 – Simcere Zaiming, an oncology-focused bipharmaceutical company and a subsidiary of Simcere Pharmaceutical Group (2096.HK)announced ...
• Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRR...
December 7, 2025 — Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd. (2096.HK), tod...
Staff
Current Brands of Products
Innovative Product Candidates
Covering Class III Hospitals
Covering Other Hospitals & Medical Institutions